EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Efficacy and Safety of Avacopan in ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Controlled Trials

Young Ho Lee, Gwan Gyu Song

Pharmacology · 07.04.2026 · 1-20

DOI: 10.1159/000551892 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pharmacology, online erschienen am 07.04.2026. Verfasst von Young Ho Lee und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Avacopan, an oral C5a receptor antagonist, has been identified as a promising glucocorticoid-sparing agent in the management of ANCA-associated vasculitis (AAV). Although individual randomized controlled trials (RCTs) have indicated its therapeutic potential, there remains a need for comprehensive integration of efficacy and safety data to guide clinical decision-making.

Methods

We performed a meta-analysis of three pivotal RCTs—CLASSIC (n = 42), CLEAR (n = 67), and ADVOCATE (n = 331)—including a total of 440 individuals diagnosed with AAV. Primary endpoints encompassed clinical response, sustained and early remission rates, changes in renal function, as well as safety outcomes such as serious adverse events, infections, organ toxicity, hematologic complications, and glucocorticoid-related adverse effects. Summary effect estimates were derived using risk ratios (RR), mean differences (MD), and 95% confidence intervals (CI). Study heterogeneity was quantified using the I² statistic and corresponding p-values.

Results

Avacopan was associated with efficacy outcomes that were equivalent to or exceeded those achieved with standard-of-care regimens. Clinical response (RR = 1.08; 95% CI: 0.98–1.19) and early remission (RR = 2.85; 95% CI: 0.95–8.54) favored avacopan. Improvements in renal parameters, including eGFR and renal response, were consistent but modest. Notably, avacopan substantially decreased glucocorticoid-related adverse events (RR = 0.78; 95% CI: 0.70–0.87; p

Zitieren

APA

Lee, Y. H., & Song, G. G. (2026). Efficacy and Safety of Avacopan in ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Controlled Trials. Pharmacology, 1-20. https://doi.org/10.1159/000551892

Vancouver

Lee YH, Song GG. Efficacy and Safety of Avacopan in ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Controlled Trials. Pharmacology. 2026:1-20. doi:10.1159/000551892

BibTeX
@article{Lee2026,
  author = {Lee, Young Ho and Song, Gwan Gyu},
  title = {Efficacy and Safety of Avacopan in ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Controlled Trials},
  journal = {Pharmacology},
  year = {2026},
  pages = {1--20},
  doi = {10.1159/000551892}
}
Kostenlos starten →